Impax Labs Now Co-Promoting Pfizer's Lyrica
From Associated Press (April 15, 2010)
HAYWARD, Calif. -- Impax Laboratories Inc. said Thursday it revised an agreement with Pfizer Inc. and is now co-promoting Pfizer’s pain and seizure drug Lyrica rather than its antidepressant Pristiq.
On April 1, Impax started marketing Lyrica to neurologists as a treatment for partial onset seizures in adults. The drug is approved as a treatment for nerve pain, seizures, and fibromyalgia. It began co-promoting Pristiq in July 2009 under terms of an agreement with Wyeth, which was acquired by Pfizer later in the year.
Impax shares rose 25 cents to close Thursday at $17.70. Pfizer
gave up 8 cents to $16.99.
Posted: April 2010